Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide.


Journal

Australian and New Zealand journal of public health
ISSN: 1753-6405
Titre abrégé: Aust N Z J Public Health
Pays: United States
ID NLM: 9611095

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 01 09 2018
revised: 01 12 2018
accepted: 01 02 2019
pubmed: 9 4 2019
medline: 6 8 2019
entrez: 9 4 2019
Statut: ppublish

Résumé

Assess national and jurisdictional incidence and mortality trends for primary liver cancer in Australia. Analysis of Australian Cancer Incidence and Mortality data published in 2017 by the AIHW. Age-standardised rates (ASR) for 1982 to 2014/2015. Piecewise linear regression was used to assess temporal trends. For the purposes of comparison, data were also extracted for all cancers with greater burdens of disease (lung, colorectal, breast, prostate, pancreatic, and brain cancers and melanoma of the skin). Since 1982, the average annual percentage change (AAPC) for ASR incidence of liver cancer was 4.858% (95%CI 4.558-5.563). This marked a 306% increase from 1.822/100,000 persons (95%CI 1.586-2.058) in 1982 to 7.396/100,000 persons (95%CI 7.069-7.723) in 2014. AAPC for ASR mortality was 3.013% (95%CI 2.448-3.521): an increase of 184% from 2.323/100,000 persons (95%CI 2.052-2.594) in 1982 to 6.593/100,000 (95%CI 6.290-6.896) in 2015. ASR incidence and mortality were highest in the NT (12.607/100,000 persons), VIC (8.229/100,000) and NSW (7.798/100,000). In comparison to the other selected cancers, higher AAPC for both incidence and mortality of liver cancer were observed. Incidence and mortality associated with liver cancer have increased substantially in the past three decades, in contrast to the improved outcomes observed for many other cancers. Jurisdictional incidence rates reflect higher prevalence of hepatitis B and C. Implications for public health: In the context of Australian cancer prevention and care programs, liver cancer is an outlier. Strategies to mitigate risk factors and improve surveillance of liver health for at-risk groups are urgently required.

Identifiants

pubmed: 30958629
doi: 10.1111/1753-6405.12889
doi:

Types de publication

Journal Article

Langues

eng

Pagination

267-273

Informations de copyright

© 2019 The Authors.

Auteurs

Fiona Cocker (F)

Menzies Institute for Medical Research, University of Tasmania.

Kwang Chien Yee (K)

Royal Hobart Hospital, Hobart, Tasmania.
School of Medicine, University of Tasmania.

Andrew J Palmer (AJ)

Menzies Institute for Medical Research, University of Tasmania.

Barbara de Graaff (B)

Menzies Institute for Medical Research, University of Tasmania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH